Download PDFPDF

1360 Treatment with a novel hexavalent OX40 agonist remodels the tumor microenvironment to favor anti-tumor immunity in mice
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address